Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 771 to 780 of 1090 total matches.
A New Rotavirus Vaccine
The Medical Letter on Drugs and Therapeutics • Aug 25, 2008 (Issue 1293)
Einstein College of
Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D ...
Rotarix, an oral live-attenuated rotavirus vaccine, has been approved by the FDA for prevention of rotavirus gastroenteritis in infants and children. Rota-Shield was withdrawn from the market because of an association with intussusception. RotaTeq, an oral live, human-bovine reassortant rotavirus vaccine, is recommended by the American Academy of Pediatrics as a routine immunization.
Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
reactions can occur with ceftazidime/avibactam.
DRUG INTERACTIONS — In vitro, avibactam is
a substrate ...
The FDA has approved ceftazidime/avibactam
(Avycaz – Actavis) for IV treatment of complicated
urinary tract and intra-abdominal infections in adults
who have limited or no other treatment options.
Ceftolozane/tazobactam (Zerbaxa – Cubist), another
cephalosporin/beta-lactamase inhibitor combination,
was approved in 2014.
Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
INTERACTIONS — Vowst contains live bacterial
spores; concurrent administration of antibacterial
drugs ...
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live
fecal microbiota spores, for prevention of additional
recurrences of Clostridioides difficile infection (CDI)
in adults. Vowst is the first orally administered
microbiota-based treatment to be approved for
this indication. A rectally-administered live fecal
microbiota-based suspension (Rebyota) was
approved in 2022 for the same indication. Neither
product is approved for acute treatment of CDI.
Med Lett Drugs Ther. 2023 May 29;65(1677):81-2 doi:10.58347/tml.2023.1677a | Show Introduction Hide Introduction
The EarCheck Middle Ear Monitor for Detection of Middle Ear Effusion in Children
The Medical Letter on Drugs and Therapeutics • Jul 14, 2008 (Issue 1290)
of
Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D., University of Washington ...
The EarCheck Middle Ear Monitor (Innovia Medical) is a device marketed to consumers for home detection of middle-ear effusion (MEE) in children.
Melatonin for Insomnia in Children
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
of melatonin that occur at the onset of puberty.11,12
DRUG INTERACTIONS — Melatonin is metabolized ...
Over-the-counter products containing melatonin are
widely used as sleep aids in children and adults.
Lumateperone (Caplyta) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020 (Issue 1603)
an increased risk of death in elderly patients with
dementia-related psychosis.
DRUG INTERACTIONS ...
The FDA has approved lumateperone (Caplyta —
Intracellular Therapies), an oral second-generation
antipsychotic, for once-daily treatment of schizophrenia
in adults. It is the 13th second-generation antipsychotic
drug to be approved by the FDA for this indication.
Cholesterol Rethink for High-Risk Patients
The Medical Letter on Drugs and Therapeutics • May 10, 2004 (Issue 1182)
INTERACTIONS — The risk of statin-induced myopathy increases with concomitant use of certain drugs. Simvastatin ...
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been considered optimal.
Coenzyme Q10
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006 (Issue 1229)
product-drug interactions. Am J Health Syst Pharm 2002; 59:339.
20. J Engelsen et al. Effect of coenzyme ...
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination products.
Ranolazine (Ranexa) for Chronic Angina
The Medical Letter on Drugs and Therapeutics • Jun 05, 2006 (Issue 1236)
with ranolazine to date, but the number of patients
treated with the drug is still small.
DRUG INTERACTIONS ...
The FDA has approved the marketing of extended release (ER) ranolazine (Ranexa - CV Therapeutics) for treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs. It should be used in combination with a nitrate, a beta-blocker or the dihydropyridine calcium-channel blocker amlodipine (Norvasc), and appears to be more effective in men. The labeling for ranolazine specifies amlodipine as the calcium-channel blocker of choice because the use of other dihydropyridines with ranolazine has not been studied, and use with diltiazem (Cardizem, and...
AmpliChip CYP450 Test
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005 (Issue 1215)
of the effects of
codeine and prediction of drug interactions. J Pharmacol Exp
Ther 1996; 278:1165.
9. T Rau ...
The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the metabolizer status of the patient. The test is intended to help guide clinicians in prescribing individualized drug therapy. About 25% of all drugs, including many antidepressants and antipsychotics, are substrates of either CYP2D6 or CYP2C19. The test is being promoted initially to psychiatrists.